Opko

News items for in vitro diagnostics industry for the week of August 31, 2020.

Of the 28 companies in the index, 12 firms saw their stock prices increase, while 16 firms' share prices decreased. 

While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.

GeneDx will provide whole-exome and whole-genome sequencing, among other services, to neonatal intensive care units staffed with Pediatrix-affiliated doctors.

Of the 28 companies in the index, 22 firms saw their stock prices increase, while six firms' share prices decreased.

Opko's BioReference Laboratories business processed about 2.2 million COVID-19 molecular tests during the quarter, it said.

The company's revenues for its 4Kscore prostate cancer test were impacted partially by the COVID-19 pandemic, Opko said.

Of the 28 companies in the index, 27 firms saw their stock prices increase, while one firm's share price decreased slightly.